Eukaryotic initiation factor 4E variants alter the morphology, proliferation, and colony-formation properties of MDA-MB-435 cancer cells

Molecular Carcinogenesis

Volumn 46, Issue 1, 2007, Pages 71-84

  Goldson, Tovë M ^a   Vielhauer, George ^b   Staub, Eveline ^a   Miller, Steve ^b   Shim, Hyunsuk ^a   Hagedorn, Curt H ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Cancer biology; m7G cap dependent translation; RNA cap binding proteins; Translation factor elF4E; Translational biology

Indexed keywords

CAP BINDING PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INITIATION FACTOR 4E; MESSENGER RNA; REGULATOR PROTEIN; VASCULOTROPIN;

5' UNTRANSLATED REGION; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESEARCH; CELL INVASION; CELL PROLIFERATION; CELL STRUCTURE; COLON CANCER; CONTROLLED STUDY; EUKARYOTE; FUNCTIONAL PROTEOMICS; GC RICH SEQUENCE; HEAD CANCER; HUMAN; HUMAN CELL; METASTASIS; NECK CANCER; PHENOTYPE; POLYSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; PROTEIN TARGETING; RNA STRUCTURE; RNA TRANSLATION; TRANSLATION INITIATION; TRANSLATION REGULATION; WILD TYPE;

5' UNTRANSLATED REGIONS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; IMMUNOBLOTTING; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; POLYRIBOSOMES; PROTEIN BIOSYNTHESIS; RNA CAPS; STAUROSPORINE; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VARIATION (GENETICS); VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EUKARYOTA;

EID: 33846246799     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20276     Document Type: Article

References (65)

1. Aoki M, Vogt PK. Retroviral oncogenes and TOR. Curr Top Microbiol Immunol 2004;279:321-338.
2. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004;23:3189-3199.
3. Whitmarsh AJ, Davis RJ. A central control for cell growth. Nature 2000;403:255-256.
4. Sonenberg N, Gingras AC. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 1998; 10:268-275.
5. Rhoads RE. Protein synthesis, cell growth and oncogenesis. Curr Opin Cell Biol 1991;3:1019-1024.
6. Ruggero D, Montanaro L, Ma L, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Mycin lymphomagenesis. Nat Med 2004;10:484-486.
7. Cormier P, Pyronnet S, Salaun P, Mulner-Lorillon O, Sonenberg N. Cap-dependent translation and control of the cell cycle. Prog Cell Cycle Res 2003;5:469-475.
8. Watkins SJ, Norbury CJ. Translation initiation and its deregulation during tumorigenesis. Br J Cancer 2002;86: 1023-1027.
9. Hiremath LS, Webb NR, Rhoads RE. Immunological detection of the messenger RNA cap-binding protein. J Biol Chem 1985;260:7843-7849.
10. Duncan R, Milburn SC, Hershey JW. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F. J Biol Chem 1987;262:380-388.
11. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-963.
12. Graff JR, Zimmer SG. Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis 2003;20:265-273.
13. Koromilas AE, Lazaris-Karatzas A, Sonenberg N. mRNAs containing extensive secondary structure in their 5′ non-coding region translate efficiently in cells overexpressing initiation factor eIF-4E [published erratum appears in EMBO J 1992 December;11(13):5138]. EMBO J 1992;11:4153-4158.
14. Grens A, Scheffler IE. The 5′-and 3′-untranslated regions of ornithine decarboxylase mRNA affect the translational efficiency. J Biol Chem 1990;265:11810-11816.
15. Defatta RJ, De Benedetti A. Translational upregulation of yes accompanies eIF4E-mediated oncogenic transformation. Int J Oncol 2003;23:1709-1713.
16. Shantz LM, Coleman CS, Pegg AE. Expression of an ornithine decarboxylase dominant-negative mutant reverses eukaryotic initiation factor 4E-induced cell transformation. Cancer Res 1996;56:5136-5140.
17. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Harris AL. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 1998; 77:2120-2128.
18. Nathan CA, Carter P, Liu L, et al. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997;15:1087-1094.
19. Fagan RJ, Lazaris-Karatzas A, Sonenberg N, Rozen R. Translational control of ornithine aminotransferase. Modulation by initiation factor eIF-4E. J Biol Chem 1991;266: 16518-16523.
20. Abid MR, Li Y, Anthony C, De Benedetti A. Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication. J Biol Chem 1999;274:35991-35998.
21. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000;82:161-166.
22. DeFatta RJ, Turbat-Herrera EA, Li BD, Anderson W, De Benedetti A. Elevated expression of eIF4E in confined early breast cancer lesions: Possible role of hypoxia. Int J Cancer 1999;80:516-522.
23. McClusky DR, Chu Q, Yu H, et al. A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer. Ann Surg 2005;242:584-590; discussion 590-592.
24. Nathan CA, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J. Analysis of surgical margins with the molecular marker eIF4E: A prognostic factor in patients with head and neck cancer. J Clin Oncol 1999;17:2909-2914.
25. Nathan CA, Franklin S, Abreo FW, et al. Expression of eIF4E during head and neck tumorigenesis: Possible role in angiogenesis. Laryngoscope 1999;109:1253-1258.
26. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999;18:2507-2517.
27. Sorrells DL, Black DR, Meschonat C, et al. Detection of eIF4E gene amplification in breast cancer by competitive PCR. Ann Surg Oncol 1998;5:232-237.
28. Anthony B, Carter P, De Benedetti A. Overexpression of the proto-oncogene/translation factor 4E in breast- carcinoma cell lines. Int J Cancer 1996;65:858-863.
29. Li BD, Gruner JS, Abreo F, et al. Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 2002;235:732-738; discussion 738-739.
30. Rhoads RE, Joshi-Barve S, Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: Effects on mRNA discrimination, cellular growth rate, and oncogenesis. Prog Nucleic Acid Res Mol Biol 1993;46:183-219.
31. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990;345:544-547.
32. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993;13:7358-7363.
33. Kevil CG, De Benedetti A, Payne DK, Coe LL, Laroux FS, Alexander JS. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: Implications for tumor angiogenesis. Int J Cancer 1996;65:785-790.
34. Lazaris-Karatzas A, Smith MR, Frederickson RM, et al. Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev 1992;6:1631-1642.
35. Sorrells DL, Meschonat C, Black D, Li BD. Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor. J Surg Res 1999;85: 37-42.
36. DeFatta RJ, Nathan CA, De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line, Laryngoscope 2000;110: 928-933.
37. Rinker-Schaeffer CW, Graff JR, De Benedetti A, Zimmer SG, Rhoads RE. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. Int J Cancer 1993;55:841-847.
38. De Benedetti A, Joshi-Barve S, Rinker-Schaeffer C, Rhoads RE. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol Cell Biol 1991;11:5435-5445.
39. Graff JR, Boghaert ER, De Benedetti A, et al. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. Int J Cancer 1995;60:255-263.
40. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 1997;89:951-961.
41. Hagedorn CH, Spivak-Kroizman T, Friedland DE, Goss DJ, Xie Y. Expression of functional eIF-4Ehuman: Purification, detailed characterization, and its use in isolating eIF-4E binding proteins. Protein Expr Purif 1997;9:53-60.
42. Hsu PC, Hodel MR, Thomas JW, Taylor LJ, Hagedorn CH, Hodel AE. Structural requirements for the specific recognition of an m7G mRNA cap. Biochemistry 2000;39:13730-13736.
43. Marcotrigiano J, Gingras AC, Sonenberg N, Burley SK. X-ray studies of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Nucleic Acids Symp Ser 1997;36: 8-11.
44. Saghir AN, Tuxworth WJ Jr., Hagedorn CH, McDermott PJ. Modifications of eukaryotic initiation factor 4F (eIF4F) in adult cardiocytes by adenoviral gene transfer: Differential effects on eIF4F activity and total protein synthesis rates. Biochem J 2001;356:557-566.
45. Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization. In Vitro 1978;14:911-915.
46. Bandyopadhyay A, Cibull ML, Sun LZ. Isolation and characterization of a spontaneously transformed malignant mouse mammary epithelial cell line in culture. Carcinogenesis 1998;19:1907-1911.
47. Bandyopadhyay A, Elkahloun A, Baysa SJ, Wang L, Sun LZ. Development and gene expression profiling of a metastatic variant of the human breast cancer MDA-MB-435 cells. Cancer Biol Ther 2005;4:168-174.
48. Cifone MA, Fidler IJ. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 1980;77: 1039-1043.
49. Li L, Price JE, Fan D, Zhang RD, Bucana CD, Fidler IJ. Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J Natl Cancer Inst 1989;81:1406-1412.
50. Sun L, Wu G, Willson JK, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994;269:26449-26455.
51. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: A survival mechanism for carcinoma cells. J Cell Biol 2002;158:165-174.
52. Harbour JW, Dean DC. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes Dev 2000;14:2393-2409.
53. Rosenwald IB, Kaspar R, Rousseau D, et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. J Biol Chem 1995;270:21176-21180.
54. Halaban R. Melanoma cell autonomous growth: The Rb/E2F pathway. Cancer Metastasis Rev 1999;18:333-343.
55. Li S, Perlman DM, Peterson MS, et al. Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem 2004;279:21312-21317.
56. Li S, Takasu T, Perlman DM, et al. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003;278: 3015-3022.
57. Polunovsky VA, Rosenwald IB, Tan AT, et al. Translational control of programmed cell death: Eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996;16:6573-6581.
58. Tan A, Bitterman P, Sonenberg N, Peterson M, Polunovsky V. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene 2000;19:1437-1447.
59. Korsmeyer SJ. Programmed cell death and the regulation of homeostasis. Harvey Lect 1999;95:21-41.
60. Harigai M, Miyashita T, Hanada M, Reed JC. A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. Oncogene 1996;12:1369-1374.
61. Biroccio A, Candiloro A, Mottolese M, et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. Faseb J 2000;14: 652-660.
62. Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: Correlation with resistance to etoposide-induced apoptosis. J Biol Chem 2002;277:12040-12046.
63. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004;24:200-216.
64. Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients. Clin Cancer Res 2003;9:2887-2892.
65. Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23: 3151-3171.